Key Highlights
- 60 Degrees Pharmaceuticals addresses a commercially available differentiated malaria prevention product targeting a significant U.S. market.
- The company plans regulatory submissions for babesiosis following orphan drug designation in 2024.
- Arakoda, approved in 2018, has been evaluated in multiple clinical studies involving over 1,100 participants.
- Leadership aims for commercial growth through pipeline expansion and market development.
60 Degrees Pharmaceuticals is focusing on a commercially available differentiated malaria prevention product while expanding its development efforts for tick-borne diseases. The company’s FDA-approved drug Arakoda serves as the foundation of its commercial strategy as it prepares for future regulatory submissions in new indications. This approach aligns with global health trends, where malaria remains a persistent challenge, with an estimated 249 million cases reported worldwide in 2022.
Arakoda Anchors Commercial Strategy
Arakoda, approved by the FDA in 2018, is a prophylactic therapy designed to protect against malaria. Its dosing schedule and clinical profile have positioned it as a relevant option in prevention. Since its launch, the company has established distribution channels in the U.S. targeting travelers and other at-risk populations.
Clinical evaluations, including eight published studies with over 1,100 participants, have demonstrated its safety and tolerability. While G6PD screening is required before use, the company has implemented measures to support healthcare providers in this process.
Pipeline Expansion Targets Tick-Borne Diseases
In addition to malaria, 60 Degrees is developing treatments for babesiosis, a tick-borne infection with increasing incidence. The FDA granted orphan drug designation for this indication in 2024, providing regulatory advantages for future development. The company’s intellectual property portfolio includes multiple patents, offering potential long-term protection for its innovations.
With key patents extending into the next decade, the company has a strategic window to advance its pipeline.
Commercial Growth Aligns With Market Trends
60 Degrees is working toward sustained commercial growth by expanding the use of Arakoda and advancing its pipeline. The leadership team, which includes professionals with experience in drug development and commercialization, is focused on scaling the product’s reach. Kristen Landon, Chief Commercial Officer, joined in 2024, bringing expertise in launching pharmaceutical brands.
The company continues to manage operational considerations, including manufacturing partnerships and regulatory requirements for new indications.
Next Steps in Development
The company’s progress toward regulatory submissions for babesiosis will be closely watched, as it could open new opportunities for Arakoda. Success in this area would support the company’s broader strategy in addressing infectious diseases. With malaria and tick-borne illnesses remaining significant public health concerns, 60 Degrees is positioned to contribute to these therapeutic areas.
The company’s ability to execute on its development plans will determine its future commercial trajectory.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...